JP2022515128A5 - - Google Patents
Info
- Publication number
- JP2022515128A5 JP2022515128A5 JP2021535545A JP2021535545A JP2022515128A5 JP 2022515128 A5 JP2022515128 A5 JP 2022515128A5 JP 2021535545 A JP2021535545 A JP 2021535545A JP 2021535545 A JP2021535545 A JP 2021535545A JP 2022515128 A5 JP2022515128 A5 JP 2022515128A5
- Authority
- JP
- Japan
- Prior art keywords
- exon
- mutation
- her2
- poziotinib
- tki
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862784084P | 2018-12-21 | 2018-12-21 | |
| US62/784,084 | 2018-12-21 | ||
| PCT/US2019/068153 WO2020132633A1 (en) | 2018-12-21 | 2019-12-20 | Combination therapy for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022515128A JP2022515128A (ja) | 2022-02-17 |
| JP2022515128A5 true JP2022515128A5 (enExample) | 2022-12-27 |
| JP7564806B2 JP7564806B2 (ja) | 2024-10-09 |
Family
ID=71102908
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535545A Active JP7564806B2 (ja) | 2018-12-21 | 2019-12-20 | がんの処置のための併用療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220041751A1 (enExample) |
| EP (1) | EP3897650A4 (enExample) |
| JP (1) | JP7564806B2 (enExample) |
| KR (1) | KR20210107023A (enExample) |
| CN (1) | CN113271948B (enExample) |
| AU (1) | AU2019406210A1 (enExample) |
| BR (1) | BR112021011493A2 (enExample) |
| CA (1) | CA3121807A1 (enExample) |
| IL (1) | IL284162A (enExample) |
| MA (1) | MA54559A (enExample) |
| MX (1) | MX2021007554A (enExample) |
| PH (1) | PH12021551276A1 (enExample) |
| SG (1) | SG11202105736QA (enExample) |
| WO (1) | WO2020132633A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3094108A1 (en) * | 2018-03-27 | 2019-10-03 | Board Of Regents, The University Of Texas Systems | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations |
| PH12021552110A1 (en) * | 2019-03-29 | 2022-06-06 | Univ Texas | Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions |
| WO2023061472A1 (zh) * | 2021-10-14 | 2023-04-20 | 江苏恒瑞医药股份有限公司 | 抗her2抗体药物偶联物和酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA46852A (fr) * | 2016-11-17 | 2019-09-25 | Univ Texas | Composés à activité antitumorale contre des cellules cancéreuses porteuses de mutations egfr ou her2 exon 20 |
| CA3094108A1 (en) * | 2018-03-27 | 2019-10-03 | Board Of Regents, The University Of Texas Systems | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations |
| SG11202012067YA (en) * | 2018-06-25 | 2021-01-28 | Spectrum Pharmaceuticals Inc | Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof |
-
2019
- 2019-12-20 CN CN201980087140.8A patent/CN113271948B/zh active Active
- 2019-12-20 BR BR112021011493-9A patent/BR112021011493A2/pt not_active Application Discontinuation
- 2019-12-20 JP JP2021535545A patent/JP7564806B2/ja active Active
- 2019-12-20 EP EP19899260.4A patent/EP3897650A4/en active Pending
- 2019-12-20 CA CA3121807A patent/CA3121807A1/en active Pending
- 2019-12-20 KR KR1020217020491A patent/KR20210107023A/ko active Pending
- 2019-12-20 AU AU2019406210A patent/AU2019406210A1/en not_active Abandoned
- 2019-12-20 MX MX2021007554A patent/MX2021007554A/es unknown
- 2019-12-20 SG SG11202105736QA patent/SG11202105736QA/en unknown
- 2019-12-20 WO PCT/US2019/068153 patent/WO2020132633A1/en not_active Ceased
- 2019-12-20 US US17/416,227 patent/US20220041751A1/en active Pending
- 2019-12-20 MA MA054559A patent/MA54559A/fr unknown
-
2021
- 2021-05-31 PH PH12021551276A patent/PH12021551276A1/en unknown
- 2021-06-17 IL IL284162A patent/IL284162A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7265985B2 (ja) | Ｅｇｆｒまたはｈｅｒ２のエクソン２０変異を有するがん細胞に対する抗腫瘍活性を有する化合物 | |
| Prelaj et al. | Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: results from the expanded access program | |
| Kim et al. | Phase 1 studies of poziotinib, an irreversible pan-HER tyrosine kinase inhibitor in patients with advanced solid tumors | |
| JP2022527788A5 (enExample) | ||
| Martinez-Useros et al. | The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas | |
| JP2022529016A5 (enExample) | ||
| JP2022529945A5 (enExample) | ||
| CN111867586A (zh) | 用于治疗具有egfr激活突变的癌症的方法 | |
| US11654145B2 (en) | Combination therapy involving diaryl macrocyclic compounds | |
| WO2020030977A2 (en) | Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors | |
| JP2022544485A (ja) | Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置 | |
| JP2024041781A (ja) | チロシンキナーゼ阻害剤と併用してｅｇｆ／ｅｇｆｒ経路を抑制する方法および組成物 | |
| JP2022527499A5 (enExample) | ||
| CN107205933A (zh) | Raf抑制剂与aurora激酶抑制剂的组合 | |
| JP2021519306A5 (enExample) | ||
| Xie et al. | Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer | |
| US20210260064A1 (en) | Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof | |
| TWI842966B (zh) | 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途 | |
| CN115698338A (zh) | 用妥卡替尼治疗her2突变型癌症的方法 | |
| Grellety et al. | A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy | |
| JP7334194B2 (ja) | Ｔｐ５３突然変異状態及び高頻度突然変異状態に基づくがん治療法 | |
| CN119604291A (zh) | Blu-945联合奥斯替尼治疗非小细胞肺癌 | |
| Utsunomiya et al. | Secondary c-kit mutation in a recurrent gastrointestinal stromal tumor under long-term treatment with imatinib mesylate: report of a case | |
| RU2021121207A (ru) | Комбинированная терапия для лечения рака | |
| JP2019123671A (ja) | 前立腺がんの予防又は治療剤 |